mRNA |
Compound 1541A |
CTRPv2 |
pan-cancer |
AAC |
-0.0078 |
0.8 |
mRNA |
681640 |
GDSC1000 |
pan-cancer |
AAC |
-0.0073 |
0.8 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0069 |
0.8 |
mRNA |
Cetuximab |
GDSC1000 |
pan-cancer |
AAC |
0.0063 |
0.8 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.007 |
0.9 |
mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0065 |
0.9 |
mRNA |
DBeQ |
CTRPv2 |
pan-cancer |
AAC |
0.0068 |
0.9 |
mRNA |
BRD-K64610608 |
CTRPv2 |
pan-cancer |
AAC |
-0.0071 |
0.9 |
mRNA |
ciclosporin |
CTRPv2 |
pan-cancer |
AAC |
-0.0069 |
0.9 |
mRNA |
fulvestrant |
CTRPv2 |
pan-cancer |
AAC |
-0.33 |
0.9 |